QUANTUM X LABS INC.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

QXL$3.31-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Interim Condensed Consolidated Statements of Operations (unaudited)

For the six months ended June 30, · For the three months ended June 30,
Note · 2026 · 2025 · 2026 · 2025
Revenues			646	899		293	370
Costs and Expenses:
Traffic-acquisition and related costs			266	184		134	50
Research and development			185	36		185	20
Selling and marketing			51	50		26	30
General and administrative			1,515	755		1,015	558
Depreciation and amortization			452	408		228	235
Other expenses, net			122	544		100	500
Operating loss			(1,945)	(1,078)		(1,395)	(1,023)
Gain from deconsolidation of CliniQuantum		6.D	3,831	-		3,831	-
Financial expenses, net			184	10,528		113	7,661
Income (loss) from continuing operations, before taxes			1,702	(11,606)		2,323	(8,684)
Tax benefit			(110)	(25)		(94)	(67)
Net income (loss) from continuing operations			1,812	(11,581)		2,417	(8,617)
Net loss from discontinued operations			-	(4,681)		-	(3,801)
Net income (loss)			1,812	(16,262)		2,417	(12,418)
Less: net loss attributable to non-controlling interests			(68)	(936)		(68)	(760)
Net income (loss) attributable to shareholders of Quantum X Labs Inc.			1,880	(15,326)		2,485	(11,658)
Net income (loss) from continuing operations attributable to:
Shareholders of Quantum X Labs Inc.			1,880	(11,581)		2,485	(8,617)
Non-controlling interests			(68)	-		(68)	-
Net loss from continuing operations			1,812	(11,581)		2,417	(8,617)
Net loss from discontinued operations attributable to:
Shareholders of Quantum X Labs Inc.			-	(3,745)		-	(3,041)
Non-controlling interests			-	(936)		-	(760)
Net loss from discontinued operations			-	(4,681)		-	(3,801)
Net income (loss) per share from continuing operations attributed to shareholders:		11
Basic			0.15	(1.83)		0.17	(1.19)
Diluted			0.10	(1.83)		0.12	(1.19)
Net loss per share from discontinued operations – Basic and diluted attributed to shareholders:			-	(0.59)		-	(0.42)
Total net income (loss) per share attributed to shareholders:		11
Basic			0.15	(2.42)		0.17	(1.61)
Diluted			0.10	(2.42)		0.12	(1.61)
Weighted average number of shares (*):
Basic	(*)		12,903,662	6,330,104	(*)	14,292,085	7,235,599	(*)
Diluted	(*)		19,043,862	6,330,104	(*)	20,074,625	7,235,599	(*)

(*)	Share and per share data in these financial statements for periods preceding the Reverse Stock Split have been retrospectively adjusted to reflect a number of shares that is equivalent to the number of shares of the Company post the Reverse Stock Split (see note 10.G).

-6-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.